Chris Viehbacher, Biogen CEO (Suzanne Kreiter/The Boston Globe via Getty Images)

Will slow up­take of Leqem­bi pose a risk to Bio­gen’s re­cov­ery?

If Bio­gen’s dis­mal stock per­for­mance on Tues­day is any in­di­ca­tion, Leqem­bi could be the sin­gle biggest fac­tor in the com­pa­ny’s abil­i­ty to right the ship …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.